Nuclear Receptors as Regulators of Immunity

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 444

Special Issue Editors

E-Mail Website
Guest Editor
Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, University of Lille, F-59000 Lille, France
Interests: nuclear receptors; macrophages; metabolism; free fatty acids; adipose tissue; obesity; liver
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Nuclear Receptors, Cardiovascular diseases and diabetes. Inserm U1011-EGID. Univ. Lille, CHU Lille, Institut Pasteur de Lille, 59000 Lille, France
Interests: nuclear receptors; immune cells; muscle

Special Issue Information

Dear Colleagues,

Nuclear receptors are ligand-regulated transcription factors involved in several physiological processes such as lipid and glucose metabolism, development, circadian rhythm and immunity. Notably, several nuclear receptors, including the glucocorticoid receptor (GR), retinoic acid receptors (RARs), peroxisome proliferator-activated receptors (PPARs), Rev-Erbs, RAR-related orphan receptors (RORs) and liver X receptors (LXRs) have been shown to play critical functions in the immune response. The identification of nuclear receptors as immune regulators and the development of synthetic ligands targeting these nuclear receptors open up new perspectives for treating immune diseases. In this Special Issue, we are pleased to invite investigators to contribute original articles or reviews that address the relationship between nuclear receptors and immunity. Research works about the role of nuclear receptors and their ligands on immune response, as well as their association with pathological conditions, are all welcome.

Dr. Laurent L’homme
Dr. Yasmine Sebti
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Nuclear receptors
  • Ligands
  • Immunity
  • Immune cells
  • Immune diseases
  • Inflammation

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop